BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644
This study is recruiting at 7 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Small Cell Lung Cancer Extensive Stage
- Small-cell Lung Cancer
- Small Cell Carcinoma
- Sclc
- SCLC,Extensive Stage
- Lung Cancer
- Lung Cancer Metastatic
- Lung Cancer Stage IV
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- SystImmune Inc.
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arkansas · 1
- Highlands Oncology Group · Springdale, AR
California · 3
- OPN Healthcare · Glendale, CA
- MemorialCare Todd Cancer Institute · Long Beach, CA
- Valkyrie Clinical Trials · Los Angeles, CA
Florida · 1
- Total Health and Research Center · Miami, FL
New Jersey · 1
- Astera Cancer Care · East Brunswick, NJ
Virginia · 1
- Virginia Cancer Specialists · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.